Video

What's Next in Immunotherapy?

Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.

Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.

During the Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting & Associated Programs, Capitini emphasized that all cancers should eventually find benefit in immunotherapy. With expansion in renal cell carcinoma (RCC), lung cancer and head and neck cancer, that change may be underway.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of Kumar.
Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.
Melanoma is a key cancer type for developing and testing immunotherapies prior to broader clinical application across other malignancies.
Image of Dr. Kumar.
Photo of a woman with shoulder-length black hair wearing a blazer
Image of a woman wearing a headband and glasses
Image of man.
Image of doctor.